Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06709573 · ClinicalTrials.gov registry record · Phase 4

Early Versus Late Adjunctive Vasopressin in Septic Shock

A Phase 4 study of Sepsis and Septic Shock, sponsored by The Cleveland Clinic.

Recruiting
Registry status
Phase 4
Development phase
300
Enrollment target
1
Study location

NCT06709573 is a Phase 4 study of Sepsis and Septic Shock that is actively recruiting participants, run by The Cleveland Clinic. The registered enrollment target is 300 participants, below the 6,561-participant average among 90 other Sepsis trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06709573, a Phase 4 study of Sepsis and Septic Shock, is actively recruiting participants, sponsored by The Cleveland Clinic.

RECRUITING
Registry status
Phase 4
Development phase
300 participants
Enrollment target
1
Study location

Study Summary

The goal of the CASPER-Pilot study is to develop clinical decision support (CDS) technology within Epic to randomize patients with septic shock to early versus standard of care vasopressin initiation. The primary aim of this study will be to test the hypothesis that CDS technology can be utilized to create two distinct cohorts of patients reflecting different times of vasopressin initiation based on norepinephrine dose requirements. Secondarily, this study will evaluate the proportion of patients whose norepinephrine dose at the time of vasopressin initiation is within the specified range for the intervention arm they were randomized to. Other outcomes of evaluation will include adherence to the developed CDS technology and comparison of clinical outcomes between the two treatment arms.

Conditions Studied

Sepsis Septic Shock

Interventions

  • DRUG vasopressin - early initiation
  • DRUG vasopressin - standard initiation

Study Locations (1)

Ohio

  • Cleveland Clinic - Cleveland

Trial Details

FieldValue
Enrollment Target 300 participants
Start Date 2025-04-29
Est. Completion 2026-05-01
Phase Phase 4

Sponsor

The Cleveland Clinic

688 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06709573

The ClinicalTrials.gov registry entry for NCT06709573 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 6,561-participant average among 90 other Sepsis trials with a reported enrollment target (95% lower). The listed sponsor is The Cleveland Clinic, which has 688 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Sepsis appearing as the primary indexed condition, and to 2 interventions - of which vasopressin - early initiation is the first listed.

NCT06709573 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.

Frequently Asked Questions

What is clinical trial NCT06709573 about?

NCT06709573 is a clinical study titled "Early Versus Late Adjunctive Vasopressin in Septic Shock". The goal of the CASPER-Pilot study is to develop clinical decision support (CDS) technology within Epic to randomize patients with septic shock to early versus standard of care vasopressin initiation. The primary aim of this study will be to test the hypothesis that CDS technology can be utilized to...

What is the current status of trial NCT06709573?

This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 300 participants. The study started on 2025-04-29. Estimated completion is 2026-05-01.

What conditions does trial NCT06709573 study?

This clinical trial studies the following conditions: Sepsis, Septic Shock.

What interventions are being tested in trial NCT06709573?

The interventions under investigation include: vasopressin - early initiation (DRUG), vasopressin - standard initiation (DRUG).

Who is sponsoring clinical trial NCT06709573?

This trial is sponsored by The Cleveland Clinic, which has 688 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06709573 being conducted?

This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Sepsis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Sepsis

All registered trials for this condition

Septic Shock

All registered trials for this condition

Ohio

All trials with a study site in Ohio

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.